Evidence map›Paper›PMID 40778123›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Neuroinflammation distinguishes HLA haplotypes in progressive supranuclear palsy.

Shelley L Forrest, Sarah S Zaheer, Ain Kim, Hidetomo Tanaka, Helen Chasiotis, Jun Li, Susan H Fox, Jinguo Wang, M Carmela Tartaglia, Anthony E Lang and 1 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shelley L ForrestTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Sarah S ZaheerRossy Centre for PSP, Toronto Western Hospital, Toronto, M5T 2S8, Ontario, Canada.
Ain KimTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Hidetomo TanakaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Helen ChasiotisTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Jun LiTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Susan H FoxRossy Centre for PSP, Toronto Western Hospital, Toronto, M5T 2S8, Ontario, Canada.
Jinguo WangLaboratory Medicine Program, University Health Network, Toronto, Canada.
M Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Anthony E LangTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Gabor G KovacsTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.ORCID 0000-0003-3841-5511

Funding

Identification of novel four repeat tauopathies through analysis of network vulnerability, tau structure and propagation.R01AG080001 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI BERNARDINO Francesco GHETTI, RUBEN VIDAL · 2023 to 2026
$2.7M
NIA NIH HHS R01 AG080001
6 · The paper itself

Abstract

Objectives: Progressive supranuclear palsy (PSP) is a neurodegenerative 4R tauopathy clinically presenting with atypical parkinsonism or cognitive behavioral changes and a relatively uniform neuropathology. We recently identified rare HLA haplotypes in PSP and now examine whether HLA haplotypes are associated with different cytopathological and clinical phenotypes. Methods: Retrospective collection of clinical data and mapping of T and B cells, microglia, and phosphorylated-tau (p-Tau) cytopathologies in 32 PSP cases. Machine learning was used to analyze whether pathological variables and their ratios, or the sequence of clinical symptoms cluster or predict HLA haplotypes. Results: Four groups were defined based on HLA haplotypes: i) 12 cases with the haplotype associated with narcolepsy ( Interpretation: PSP pathology might be associated with various etiological-pathogenic events including targetable autoimmune mechanisms. The HLA-haplotype dependent diversity of neuroinflammatory markers should be evaluated in clinical and biomarker studies in, and beyond, PSP to understand its relevance for patient stratification in disease modifying therapy trials.

Indexed as

cytotoxic T cellsHLAmachine learningmicrogliaprogressive supranuclear palsytau

Identifiers

PMID40778123
PMCPMC12330476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.